Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2024; Elsevier BV; Volume: 144; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2024-211410
ISSN1528-0020
AutoresNico Gagelmann, Friedrich Stölzel, Roland Fenk, Tobias A.W. Holderried, Fabian Mueller, Natalia Tovar, Aina Oliver‐Caldés, Kristin Rathje, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Anca Maria Albici, Natalie Schub, Friederike Schmitz, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Nicolaus Kroeger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Maximilian Merz,
Tópico(s)Protein Degradation and Inhibitors
Referência(s)